North America Cardiac Ablation Market size exceeded USD 1.4 billion in 2021 and is set to observe around 14.2% growth rate from 2022 to 2028. The industry growth is primarily attributed to growing patient preference for advanced minimally invasive technologies in developed and developing economies. Moreover, numerous benefits offered by such minimally invasive procedures including rapid recovery, reduced surgical complications, shorter procedural time will positively influence the market revenue.

Get more details on this report - Request Free Sample PDF

In addition, several market players, as well as governments, are undertaking several initiatives and campaigns for awareness regarding cardiac health and associated treatments in the region. For instance, the National Heart, Lung, and Blood Institute celebrate February as the American heart month for cardiovascular health awareness each year in the U.S. Similarly, the Canadian Women's Heart Health Alliance organize wear red Canada campaign across Canada on February 13^th, annually to raise awareness regarding women’s heart health.

Rising number of patients with heart diseases coupled with increasing healthcare expenditure are the factors propelling the market outlook. For instance, the total health expenditure for atrial fibrillation is around USD 26 billion per year in the U.S. Furthermore, the surge in patient hospitalizations for several cardiovascular complications will proliferate the demand for the cardiac ablation market. According to the Centers for Disease Control and Prevention (CDC), each year more than 750,000 hospitalizations and around 130,000 deaths are reported owing to atrial fibrillation.

The COVID 19 pandemic has adversely impacted the cardiac ablation industry. Restrictions on elective procedures in clinical settings limit the overall market size. Furthermore, preventive lockdown in several countries, a temporary ban of import and export services, shutdown in manufacturing units has negatively impacted sales of cardiac ablation products. However, growing awareness about heart diseases and the adoption of minimally invasive procedures among the population will stimulate the regional industry growth.

North America Market, By Product

The radiofrequency ablators segment will showcase 13.8% CAGR during the forecast period. The segment growth is owing to high product availability and accessibility in the significant market. Moreover, radiofrequency ablation procedures are offering numerous benefits such as high survival rate, quick relief, minimal procedural time with cost-effectiveness will impel the market expansion.

North America Market, By Approach

Get more details on this report - Request Free Sample PDF

The catheter-based segment dominated over 74% market share in 2021 propelled by high adoption of catheter-based ablation procedures. Moreover, increasing the patient pool of atrial fibrillation and cardiac arrhythmia in the region will augment segment growth potential. Further, catheter-based ablation offers several advantages such as reduced recurrence, shorter procedural time, minimal risk of adverse events.

North America Cardiac Ablation Market, By Application

The atrial fibrillation and flutter segment accounted more than USD 962 million revenue in 2021, due to growing prevalence of atrial fibrillation along with the availability of advanced treatments. For instance, according to the Centers for Disease Control and Prevention (CDC), around 2 percent of people below 65 years old and about 9 percent of people ages 65 and older suffer from atrial fibrillation in U.S.

North America Market, By End-use

 Hospitals held around 56% North America market share in 2021. Rising number of patient visits leading to a high rate of disease treatments performed in hospital settings will impel the demand for cardiac ablation procedures. Furthermore, expanding sophisticated healthcare infrastructure and high adoption advanced technology enabled devices will positively influence the patient preference towards hospital settings.

North America Market, By Country

U.S. cardiac ablation market surpassed USD 1.2 billion revenue in 2021 and is anticipated to grow at 14.2% CAGR through 2028. Changes in lifestyle habits such as excessive drinking alcohol, tobacco consumption, smoking, obesity, and unhealthy dietary habits are leading to an increasing incidence of cardiovascular disorders.

Additionally, growing awareness regarding cardiovascular diseases and associated advanced treatments will offer lucrative market growth opportunities. Further, rising patient preference towards minimally invasive procedures will accelerate the market demand. High adoption of advanced technologies in clinical settings, favourable reimbursement scenario as well as high disposable income in the country will boost the U.S. market growth.

Competitive Industry Landscape

Prominent participants operating across the North America market include Abbott Laboratories, Biosense Webster (Johnson & Johnson), AngioDynamics, Inc, AtriCure Inc, Biotronik SE & Co. KG, Medtronic plc, Boston Scientific Corporation, MicroPort Scientific Corporation, and Stereotaxis, Inc.

These notable companies are undertaking several growth strategies to broaden market share through collaboration, acquisitions, and novel product launches. For instance, in June 2020, Boston Scientific Corporation has launched the DIRECTSENSE technology to monitor radiofrequency energy delivery effects during cardiac ablation procedures.